Key Points
- Insider sale: BeOne Medicines SVP Chan Henry Lee sold 2,666 shares for approximately $959,760, reducing his holdings by 76.65% to 812 shares. The transaction was conducted under a pre-arranged Rule 10b5-1 plan.
- Strong quarterly results: BeOne reported earnings of $2.05 per share versus the $1.40 consensus estimate, while revenue of $1.71 billion also exceeded expectations.
- Analyst sentiment remains positive: The stock has a consensus “Buy” rating and an average price target of $402.14, compared with a recent price near $356.
BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) SVP Chan Henry Lee sold 2,666 shares of the business's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $360.00, for a total transaction of $959,760.00. Following the sale, the senior vice president owned 812 shares of the company's stock, valued at $292,320. This trade represents a 76.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Chan Henry Lee also recently made the following trade(s):
- On Thursday, July 30th, Chan Henry Lee sold 1,044 shares of BeOne Medicines stock. The shares were sold at an average price of $323.69, for a total transaction of $337,932.36.
- On Wednesday, July 8th, Chan Henry Lee sold 664 shares of BeOne Medicines stock. The shares were sold at an average price of $302.46, for a total transaction of $200,833.44.
- On Tuesday, June 16th, Chan Henry Lee sold 590 shares of BeOne Medicines stock. The stock was sold at an average price of $265.98, for a total transaction of $156,928.20.
- On Thursday, June 11th, Chan Henry Lee sold 428 shares of BeOne Medicines stock. The stock was sold at an average price of $257.63, for a total transaction of $110,265.64.
- On Monday, June 8th, Chan Henry Lee sold 871 shares of BeOne Medicines stock. The stock was sold at an average price of $270.42, for a total transaction of $235,535.82.
BeOne Medicines Price Performance
Shares of NASDAQ ONC opened at $356.01 on Friday. The stock has a market cap of $39.06 billion, a price-to-earnings ratio of 62.68 and a beta of 0.49. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.06 and a current ratio of 3.40. BeOne Medicines Ltd. - Sponsored ADR has a fifty-two week low of $253.95 and a fifty-two week high of $385.22. The firm's 50-day simple moving average is $302.92 and its 200 day simple moving average is $309.24.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $2.05 EPS for the quarter, topping analysts' consensus estimates of $1.40 by $0.65. The firm had revenue of $1.71 billion during the quarter, compared to analyst estimates of $1.66 billion. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%. As a group, research analysts anticipate that BeOne Medicines Ltd. - Sponsored ADR will post 7.3 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the business. Cetera Investment Advisers bought a new position in BeOne Medicines in the 2nd quarter valued at $455,000. Rhumbline Advisers purchased a new stake in BeOne Medicines during the second quarter worth about $275,000. Arrowstreet Capital Limited Partnership bought a new stake in BeOne Medicines in the second quarter worth about $505,000. Invesco Ltd. purchased a new position in BeOne Medicines in the second quarter valued at about $422,000. Finally, EverSource Wealth Advisors LLC purchased a new position in BeOne Medicines in the second quarter valued at about $68,000. Hedge funds and other institutional investors own 48.55% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities research analysts recently issued reports on ONC shares. Royal Bank Of Canada decreased their price target on BeOne Medicines from $451.00 to $450.00 and set an "outperform" rating for the company in a report on Thursday, August 6th. Barclays lifted their price objective on shares of BeOne Medicines from $403.00 to $407.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. Weiss Ratings reiterated a "sell (d-)" rating on shares of BeOne Medicines in a research note on Friday, July 17th. Wall Street Zen upgraded shares of BeOne Medicines from a "buy" rating to a "strong-buy" rating in a report on Saturday, July 18th. Finally, JPMorgan Chase & Co. raised their price target on shares of BeOne Medicines from $415.00 to $425.00 and gave the company an "overweight" rating in a research report on Thursday, July 23rd. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, BeOne Medicines has a consensus rating of "Buy" and a consensus target price of $402.14.
Read Our Latest Stock Analysis on BeOne Medicines
Key BeOne Medicines News
Here are the key news stories impacting BeOne Medicines this week:
- Positive Sentiment: BeOne Medicines reported quarterly earnings of $2.05 per share, well above the $1.40 consensus estimate, while revenue reached approximately $1.71 billion, exceeding expectations and representing roughly 30% growth. The results reinforce the company’s commercial momentum. BeOne Medicines Q2 2026 earnings call highlights
- Positive Sentiment: UBS maintained its Buy rating on BeOne Medicines, signaling continued confidence in the company’s growth outlook and oncology portfolio. UBS maintains Buy rating on BeOne Medicines
- Positive Sentiment: BeOne’s collaboration with Revolution Medicines to fund and develop the Phase 3 RAS(ON) program could expand BeOne’s targeted-cancer pipeline and create future commercialization opportunities. Revolution Medicines’ shares rose following the announcement, suggesting investors viewed the deal as strategically meaningful. Revolution Medicines rises after BeOne-funded Phase 3 RAS(ON) deal
- Negative Sentiment: CEO John Oyler sold 240,810 shares across transactions dated August 10–12 for approximately $86.5 million, substantially reducing his direct ownership. The sales may pressure sentiment, particularly with ONC trading near its 52-week high, although they were executed under a pre-arranged Rule 10b5-1 plan and therefore may not reflect a new negative view of the company. SEC filing on John Oyler’s BeOne Medicines stock sales
BeOne Medicines Company Profile
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
